Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04252742 · ClinicalTrials.gov registry record · Phase 4
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
A Phase 4 study of Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 512
- Enrollment target
- 20
- Study locations
NCT04252742: Completed Phase 4 study of Migraine, sponsored by Amgen.
NCT04252742 is a Phase 4 study of Migraine that has completed, run by Amgen. The registered enrollment target is 512 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04252742, a Phase 4 study of Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 512 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
Primary Outcome
At least moderate headache pain intensity was defined as headache pain intensity reported as 'Moderate' or 'Severe' based on the 3-level headache pain intensity scale. Worst or peak pain intensity during a headache was collected using the e-diary in 3-levels (mild, moderate or severe). The duration of headaches with at least moderate pain intensity was collected. A negative change from baseline indicates a reduction in mean monthly hours of at least moderate headache pain intensity. Change from
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Erenumab
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Jacksonville Center for Clinical Research - Jacksonville
- Visionary Investigators Network - Miami
- Renstar Medical Research - Ocala
- Heuer Medical Doctor Research LLC - Orlando
- Neurology Associates of Ormond Beach - Ormond Beach
- Visionary Investigators Network - Pembroke Pines
Colorado
- Mountain Neurological Research Center - Basalt
- Denver Neurological Clinic - Denver
- Summit Headache and Neurologic Institute - Englewood
Missouri
- StudyMetrix Research - City of Saint Peters
- Clinvest Research LLC - Springfield
- Mercy Health Research - St Louis
California
- Long Beach Clinical Trials Services Inc - Long Beach
- Clinical Research Institute, LLC - Los Angeles
Massachusetts
- Boston Clinical Trials - Boston
- New England Regional Headache Center Inc - Worcester
Idaho
- Saint Lukes Clinic - Meridian
Illinois
- Chicago Headache Center and Research Institute - Chicago
Michigan
- Michigan Head Pain and Neurological Institute - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 4 |
What the finished NCT04252742 record still lists
NCT04252742 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04252742 names 20 study sites across 8 states, led by Florida, Colorado, Missouri.
Frequently Asked Questions
What is clinical trial NCT04252742 about?
NCT04252742 is a clinical study titled "Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine". The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
What is the current status of trial NCT04252742?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 512 participants. The study started on 2020-09-15. Estimated completion is 2023-10-26.
What conditions does trial NCT04252742 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT04252742?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT04252742?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04252742 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04252742's enrollment target sits among peer trials
512 22nd of 102 higher than 81 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI